At last, the effector CD8+ T cells recognize the antigenic peptides presented on the surface of tumour cells by major histocompatibility complex class I (MHC‐I) and transmit apoptotic signals into the tumour cells.3 Cancer vaccination and immune checkpoint therapy are developed to amplify this endogenous antitumour response3 and so are suitable for targeting immunogenic tumours that present neoantigens to CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.